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Abstract
Many common diseases of the gas exchange surface of the lung have no specific treatment but cause serious morbidity and
mortality. Idiopathic Pulmonary Fibrosis (IPF) is characterized by alveolar epithelial cell injury, interstitial inflammation,
fibroblast proliferation and collagen accumulation within the lung parenchyma. Keratinocyte Growth Factor (KGF, also
known as FGF-7) is a critical mediator of pulmonary epithelial repair through stimulation of epithelial cell proliferation.
During repair, the lung not only uses resident cells after injury but also recruits circulating bone marrow-derived cells
(BMDC). Several groups have used Mesenchymal Stromal Cells (MSCs) as therapeutic vectors, but little is known about the
potential of Hematopoietic Stem cells (HSCs). Using an inducible lentiviral vector (Tet-On) expressing KGF, we were able to
efficiently transduce both MSCs and HSCs, and demonstrated that KGF expression is induced in a regulated manner both in
vitro and in vivo. We used the in vivo bleomycin-induced lung fibrosis model to assess the potential therapeutic effect of
MSCs and HSCs. While both populations reduced the collagen accumulation associated with bleomycin-induced lung
fibrosis, only transplantation of transduced HSCs greatly attenuated the histological damage. Using double
immunohistochemistry, we show that the reduced lung damage likely occurs through endogenous type II pneumocyte
proliferation induced by KGF. Taken together, our data indicates that bone marrow transplantation of lentivirus-transduced
HSCs can attenuate lung damage, and shows for the first time the potential of using an inducible Tet-On system for cell
based gene therapy in the lung.
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Introduction
Many common diseases of the gas exchange surface of the lung
have no specific treatment but cause serious morbidity and
mortality. Injury to the lung parenchyma may result in a spectrum
of diseases from the acute respiratory distress syndrome (ARDS) to
idiopathic pulmonary fibrosis (IPF) [1]. Histologically, IPF is
characterized by alveolar epithelial cell injury/activation, intersti-
tial inflammation, fibroblast proliferation and exaggerated accu-
mulation of collagen and extracellular matrix in the parenchyma,
leading to irreversible loss of lung function. Animal models are
widely used to study the evolution of such fibrotic responses, and
the intra-tracheal administration of bleomycin is the best-
characterized experimental model of lung fibrosis [2,3,4]. Despite
its intrinsic limitations, the bleomycin model shares many clinical
features with the human disease [5,6]. Bleomycin-induced lung
fibrosis is associated with an increase in classical pro-inflammatory
cytokines including TNF-a, IL-1b and IL-6 followed by a switch to
pro-fibrotic markers (TGF-b1, fibronectin and pro-collagen-1)
[1,7]. Epithelial cell apoptosis makes a significant contribution to
the disease but type II pneumocytes appear to function as local
stem cells, and functional recovery depends on their proliferation
to restore the normal alveolar architecture [7].
Bone marrow-derived stem cells (BMDC) are being evaluated
for their therapeutic potential in several lung diseases including
pulmonary fibrosis [8,9,10]. They can both engraft in injured lung
[8,10,11,12] and in some cases are thought to acquire epithelial
characteristics [8,12,13]. Within the adult bone marrow stem cells,
there are two main populations: the hematopoietic stem cells
(HSCs) and the mesenchymal stromal cells (MSCs). It has been
described that MSCs have the ability to differentiate into multiple
cell types in vitro [14,15,16]. MSCs improve outcome in the
bleomycin model, possibly through immunosuppression and
alteration of the cytokine milieu in the inflammatory stage of
the disease process [8,17,18]. MSCs are an interesting thera-
peutic tool as it is suggested that they are immuno-privileged,
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which may allow their use for allo-transplantation therapies
[10,19,20,21,22,23,24]. On the other hand, HSCs are recognized
as the main source of adult stem cells having the ability to self-
renew and to differentiate into all blood lineages. HSCs are also
progenitors for several cell types, including endothelial [25] and
epithelial [26], myocytes [27] and neurons [28]. In the lung, some
groups have shown that HSCs are able to become alveolar type II
lung cells after bone marrow transplantation [11,13,29]. After lung
injury, the contribution of BMDC to lung repair has been reported
in different injury models, such as Lipo-polysaccharide-induced
lung injury [30], cystic fibrosis [31], radiation pneumonitis [29]
and asbestos-induced pulmonary fibrosis [32]. Nevertheless, very
little is known about the potential of HSCs in bleomycin-induced
lung fibrosis, of serving as useful vehicles to express genes that may
alter the pulmonary epithelium, regardless of their ability to
differentiate into lung cell types.
Keratinocyte growth factor (KGF), also known as FGF-7, is a
member of the fibroblast growth factor (FGF) family, and acts
specifically on epithelial cells [33]. KGF is a potent mitogenic
factor in a variety of epithelial cells including keratinocytes [34], as
well as mammary [35] and pancreatic ductal epithelia [36]. KGF
stimulates type II cell proliferation in vitro [37], and increases the
expression of surfactant proteins in cultured alveolar type II cells
[38]. Administration of exogenous rhKGF ameliorates lung injury
in a variety of animal models. KGF pre-treatment reduces lung
injury induced by acid instillation [38], bleomycin instillation [39]
and a-naphthylthiourea [40]. In the bleomycin model, KGF
improves both morphological damage to the alveolar epithelium
and inflammation [39]. Hence this cytokine is a potential specific
therapy that may aid early lung repair. However, its clinical
usefulness is still limited by its rapid degradation and difficulties in
achieving adequate delivery to the distal lung without unaccept-
able systemic effects [41,42]. Thus it is important to find a more
sustained delivery of KGF without inducing an immune response.
To enhance the level and consistency of expression of KGF in
the distal lung we developed a new stem cell-based approach using
an inducible Tet-on lentiviral vector (LV)-mediated KGF gene
delivery system [43]. Bone marrow stem cells can be efficiently
transduced by lentivirus, and maintain their self-renewal and
differentiation abilities, so we hypothesized that lentivirally
transduced bone marrow stem cells could serve as a constant
but controlled pool of KGF within the lung parenchyma.
We demonstrate here, for the first time, that this combined cell/
gene therapy is not only able to deliver KGF to the injured lung
parenchyma, but that this KGF attenuates bleomycin-induced
lung injury. We report that bone marrow derived cells expressing
KGF in the lung are able to reduce the histological hallmarks of
bleomycin-induced fibrosis, as well as induce proliferation of
alveolar type II cells and decrease collagen levels within the lungs.
Finally, comparing two different strategies using MSCs and HSCs
as therapeutic vectors, our data suggests that progeny of HSCs
may be better vehicles for gene therapy to ameliorate lung fibrosis.
Materials and Methods
Lentiviral Vector Constructs
The Tet-On inducible lentiviral vector was based on the pRRL-
cPPT-hPGK-mcs-WPRE with the reporter gene MuSEAP
encoded under the control of the hPGK promoter (kindly
provided by Dr. Olivier Danos, UCL, London) [43]. To introduce
the sequence of IRES-eGFP or mKGF-IRES-eGFP, the MuSEAP
was excised using MluI/EcoRV enzymes. The IRES-eGFP
sequence was amplified from an intermediate vector, and
restriction sites were introduced by PCR (forward 59 acg-
cacgcgtgcccctctccctccc 39; reverse 59 acgcgatatctcgagtgcggccgcttta
39), and then inserted into MluI/EcoRV sites. Using the same
strategy, the mKGF-IRES-eGFP sequence was amplified and
restriction sites introduced by PCR (forward 59 acgcacgcgtatgca-
caaatggatactgac 39; reverse 59 acgcgatatctcgagtgcggccgcttta 39),
and inserted into MluI/EcoRV sites. The mKGF cDNA was
kindly provided by Dr. JA Whitsett (Cincinnati Children’s
Hospital Medical Center, Cincinnati, USA).
Ethics Statement, Animals and Cells Lines
All animal experiments were performed in compliance with
Home Office and institutional guidelines. C57Bl/6 CD45.1 mice
were bred in-house and CD45.2 were purchased from Charles
River (UK) and quarantined for at least 7 days prior to use.
293T and HeLa cells were obtained from the ATCC and were
grown in RPMI or DMEM, supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 100 IU/ml penicillin and
100 mg/ml streptomycin (Gibco) at 37uC in a humidified
atmosphere containing 5% CO2.
Production and Titration of Lentiviral Vectors
Lentiviral vectors pseudotyped with the vesicular stomatitis G
protein (VSV-G) were generated by transfection into 293T cells of
a packaging construct, pCMVAR8.74; a plasmid producing the
VSV-G envelope (pMD.G); and the vector itself as previously
described [44]. Culture medium was collected at 48 h and 72 h,
0.45 mm filtered, concentrated approximately 400 fold by ultra-
centrifugation (Beckman), aliquoted and stored at 280uC until
used.
Viral titres of infectious particles were determined by overnight
transduction of 56104 Hela cells with serial dilutions of the virus in
a 12-well plate with 4 mg/ml Polybrene (Sigma-Aldrich, # 52495).
After transduction, medium was changed to new RPMI medium
containing 10 mg/ml doxycycline (Sigma Aldrich) supplemented
with 10% Tet-system-proved FCS (BD Biosciences, Clontech).
Seventy-two hours later cells were analyzed for eGFP expression
by flow cytometry.
Isolation, Culture, and Lentiviral Gene Transfer into
Murine MSCs
A frozen vial of murine MSCs (from male C57Bl/6 mice:
courtesy of Tulane Centre of Gene Therapy, New Orleans, USA)
was thawed and expanded by two passages as previously described
[15]. After expansion, MSCs were transduced with lentiviral
vectors carrying the eGFP reporter gene or KGF-eGFP. For
transduction, cells were seeded at 2000 cells/cm2 in a T-75 cm2
flask. The following day virus particles were added at a multiplicity
of infection (m.o.i.) of 50 for 16 hours. Cells were washed and fresh
medium added with Doxycycline (10 mg/ml) for 5 days to induce
transgene expression. To enrich eGFP or KGF-eGFP expressing
cells, MSCs were sorted using the flow-activated sorter Mo-Flo
(Becton-Dickinson, Oxford, UK). The eGFP positive fraction was
cultured for 7 or 10 days. MSCs used were between passages
10–12.
In Vitro Culture Differentiation Assay
Differentiation assays were performed as described [14].
Transduced MSCs were plated at a density of 2500 cells/cm2
under the same medium conditions as above for 24 to 48 hours.
After attachment, cells were washed with basic differentiation
medium, consisting of DMEM/2% FBS with penicillin/strepto-
mycin, and then replaced with basic differentiation medium
containing specific differentiation supplements. Osteogenic and
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adipogenic supplements were used as described [16]. Differenti-
ation medium was changed every 2–3 days and cultured for 14
days.
Gene Transfer into Murine Hematopoietic Stem Cells
Bone marrow from 8-12-week-old C57Bl/6 CD45.1 mice was
obtained by flushing the femurs, tibias and iliac crests. Lineage
negative cells were purified using the Murine Hematopoietic
Progenitor Enrichment Cocktail (Stem Cells Technologies,
Vancouver, Canada) according to the manufacturer’s instructions.
Lineage negative cells (Lin-) were pre-stimulated by culture (at 0.6-
16106 cells/ml) in StemSpan (Stem Cell Technologies) serum-free
medium containing murine SCF, Flt-3 and TPO at 50 ng/ml, and
IL-6 at 10 ng/ml (all from Peprotech, London, UK), supplement-
ed with 2% FCS, 100 IU/ml penicillin and 100 mg/ml strepto-
mycin, at 37uC, 5% CO2 for 6 hours. Viral supernatants were
added at m.o.i 30 (based on FACS titre) with 4 mg/ml Polybrene
for 12 hours. Cells were washed and injected or re-seeded to
analyse transduction efficiency or methylcellulose assay.
Hematopoietic Progenitor Assays
Lin- cells were seeded in murine MethoCultGF M3434 medium
containing SCF, IL-3, IL-6, and EPO (Stem Cell Technologies)
and doxycycline 10 mg/ml to induce gene expression, at 104 cells/
ml/35 mm2 petri dish (in triplicates). After 7 days 0.25 ml of
methylcellulose without cytokines (MethoCultGF M3234), but
with or without doxycycline was added to the dishes to maintain
gene expression induction. Both GFP+ and GFP- colonies were
scored after 12 days by fluorescence microscopy under an inverted
Leica DMIL microscope with a UV lamp (Leica Microsystems,
Heerbrugg, Switzerland).
Bone Marrow Repopulation and Peripheral Blood
Chimerism Analysis
A total of 17 eight-week-old male C57Bl/6 CD45.2 recipient
mice were lethally irradiated at 1200 cGy. 0.66106 mouse Lin-
cells from donor C57Bl/6 CD45.1 mice were injected intrave-
nously into the tail vein in 100 ml of PBS. 7 weeks after bone
marrow transplantation, mice received doxycycline in drinking
water (2 mg/ml) with 3% sucrose (Fisher laboratories). One week
after gene induction, 100–200 ml of peripheral blood was collected
in heparinized tubes, and analyzed for both chimerism and eGFP
expression by flow cytometry. Red blood cells were lysed using
ammonium chloride (Stem Cell Technologies, #07850). For
chimerism and multilineage analysis, cells were stained with rat
anti-mouse CD45.1-PE, CD45.2-APC and CD3-PE-Cy5 antibod-
ies or corresponding isotype controls (for donor CD45.1 cells and
recipient CD45.2 cells, lymphocytes and eGFP). Alternatively cells
were stained with rat anti-mouse CD45.1-APC, Gr1-PE and
Mac1-PE-Cy5 antibodies (for donor CD45.1 cells, Granulocytes,
Macrophages and eGFP cells). All antibodies were purchased from
BD Biosciences, Oxford, UK. Stained cells were analyzed by flow
cytometry LSR-II (Beckton-Dickinson).
Bleomycin-Induced Lung Injury and MSC or Lin- HSC
Administration
For the MSC studies, a total of 23 eight-week-old male C57Bl/6
mice were exposed to bleomycin (2 mg/kg, KyowaHakk, UK) or
saline by oropharyngeal (o.p.) instillation (50 ml/mouse) under
light isofluorane-induced anaesthesia. Non-transduced or trans-
duced MSCs with LV-eGFP or LV-KGF-IRES-eGFP (0.56106 in
100 ml of PBS) were injected intravenously by tail vein 8 hours
after bleomycin instillation. Three days later, a second dose of
0.56106 of MSCs was injected. Mice were maintained on drinking
water with doxycycline (2 mg/ml) and 3% sucrose to induce the
gene expression during the whole experiment. Mice were weighed
on the day of bleomycin administration and every 2 days until the
end of the experiment. Animals were sacrificed 14 days after
bleomycin administration, and the left lungs removed and used for
RNA isolation. The remaining lung was inflated with 4% PFA in
PBS at a pressure of 20 cm H2O, followed by removal of the
inflated lungs en bloc and immersion in fresh fixative. Lungs were
then processed for immunohistochemistry or, in some cases for
flow cytometry analysis (see below).
For the HSCs studies, 15 mice underwent bone marrow
transplantation with transduced Lin- cells and received bleomycin
(2 mg/kg) or saline. Nine weeks post transplantation, 3 mice were
given o.p. saline and doxycycline (Saline + KGF), 6 mice o.p.
bleomycin without doxycycline (BLM), and 6 mice o.p. bleomycin
with doxycycline (BLM+KGF). When used, doxycycline was
maintained in the drinking water (2 mg/ml) with 3% sucrose until
the end of the experiment. Mice were weighed on the day of
bleomycin administration and every 2 days until the end of the
experiment. Mice were sacrificed 14 days after bleomycin
administration. Two extra mice underwent bone marrow
transplantation with untransduced Lin2 cells, and received o.p.
saline with doxycycline. The data from these 2 mice were used
only for the type II alveolar cell proliferation analysis.
Tissue Processing and Immunohistochemistry
Inflated lungs were fixed in 4% PFA for 4 hours at 4uC and
then incubated overnight in 15% sucrose in PBS at 4uC. Tissue
was then dehydrated in 70% ethanol and embedded in paraffin.
Sections (4 mm) were stained with Haematoxylin and Eosin or
Martius Scarlet Blue stain. For semi-quantitative analysis of
fibrosis by Ashcroft Score, four different levels separated by
100 mm were analysed by two blinded independent investigators
[2].
For all antibodies used, sections required microwave antigen
retrieval (10 mM sodium citrate, pH 6 for 10 minutes), and were
quenched for endogenous peroxidase with 1.6% H2O2. The
sections were immunostained with anti-eGFP antibody (Rabbit
polyclonal: Molecular Probes, Invitrogen, UK: 1:500), anti-Ki67
(Rat monoclonal: Dako, UK: 1:25), anti-Surfactant Protein C
(Rabbit polyclonal: Chemicon, 1:100), anti-FGF-7 (KGF) (Rabbit
polyclonal: Santa Cruz, 1:100) and anti-Alpha Smooth Muscle
Actin (a-SMA) (Mouse monoclonal: Sigma, 1:1000). For GFP and
a-SMA stainings, biotinylated secondary antibody (1:250) was
used and immunoreactivity was detected using the ABC
peroxidase-based system in combination with 3, 39 diaminobenzi-
dine, following the manufacturer’s protocol. For KGF staining, the
REALTM EnvisionTM Dual Detection System (Dako) was used in
combination with 3, 39 diaminobenzidine, following the manu-
facturer’s protocol. For Ki-67 and SP-C co-staining, a secondary
goat anti-rat-Alexa 555 was used for Ki-67, and goat anti-mouse-
Alexa 488 was used for SP-C (Molecular Probes, Invitrogen, UK).
Absent and/or non-specific primary negative controls were
included. For secondary antibodies conjugated with fluoro-
chromes, sections were incubated with Sudan Black (0.1% in
70% ethanol) for 30 mins to reduce autofluorescence.
Determination of Total Lung Collagen
The total collagen content of the left lung was determined by
measuring hydroxyproline content in aliquots of pulverized left
lung as described previously [45]. Hydroxyproline was quantified
by reverse-phase high performance liquid chromatography
(HPLC) of 7-chloro-4-nitrobenzo-oxao-1,3,-diazole-derived acid
Cell Therapy for Lung Fibrosis
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hydrolysates; the total left lung collagen was then calculated in
milligrams, assuming that lung collagen contains 12.2% (w/w)
hydroxyproline.
Whole Lung Single-Cell Suspensions for Flow Cytometry
A single-cell suspension was obtained from murine lungs as
described [46] with minor modifications. Saline-perfused lung
samples were finely minced with razor blades and enzymatically
digested for 1 h at 37uC in a solution of 0.1% of Collagenase A
(Roche, # 103578), 2.4 U/ml Dispase II (Roche, # 295825) with
2.5 mM CaCl2 and DNase 0.4 mg/ml (Sigma-Aldrich, # D4513).
The resulting digestion was then filtered through a 70 mm cell
strainer (BD Biosciences, # 352340). Cells were washed with
HBSS+ solution two times before staining with the rat anti-mouse
CD45.1-PE and CD45.2-APC (BD Biosciences, Oxford, UK) for
30 minutes at 4uC. After staining, all single cell suspensions were
washed with PBS 2% FCS and stained with DAPI (100 ng/ml) for
exclusion of dead cells. Analysis was performed using an LSR-II
flow cytometer (Becton-Dickinson).
Quantitative Real-Time RT-PCR
Total RNA from frozen powdered lung tissue was isolated with
TRIzol reagent as per the manufacturer’s protocol. RNA was
DNase-treated using a DNAfree kit (Ambion, UK). Random
hexamers were used as the primer for reverse transcription (RT) of
1 mg of total RNA using the Superscript VILOTM cDNA synthesis
kit (Invitrogen, UK) following the manufacturer’s instructions. Real
time RT-PCR was conducted using the Platinum SYBR Green
qPCR SuperMix UDG (Invitrogen, UK) on a LightCycler 1.5
Real-time Detection System (Roche, UK) and analysed using
LightCycler Real-time PCR Detection System Software Version
3.5. Cycling conditions were as follows: one cycle of 50uC (2 mins),
95uC (2 mins); 45 cycles of 95uC (5 secs), 55uC (5 secs), 72uC
(15 secs). For each gene, crossing point (Cp) values were
determined and normalized by subtraction of the Cp value for
HPRT (generating a DCp value). Relative change was determined
by subtraction of the DCp value for the control sample from the
DCp value for the treated sample (DDCp value). Fold change was
subsequently calculated using the formula 22DDCp. All murine
primers used were: HPRT (Forward 59-TCATTATGCCGAG-
GATTTGG-39; Reverse 59-ACAGAGGGCCACAATGTGAT-
39), Col1a1 (Forward 59-TCATGGCTTCTCTGGTCTC-39;
Reverse 59-CCGTTGAGTCCGTCTTTGC-39), KGF (Forward
59-TTGACAAACGAGGCAAAGTG-39; Reverse 59- CCCTTT-
GATTGCCACAATTC-39). TNFa (Forward 59-CAAATGGC-
CTCCCTCTCAT-39; Reverse 59-CACTTGGTGGTTTGC-
TACGA-39), CCL2 (Forward 59-AGCTCTCTCTTCCTCCAC-
CAC-39; Reverse 59-CGTTAACTGCATCTGGCTGA-39) and
CCL9 (Forward 59-TACTGCCCTCTCCTTCCTCA-39; Re-
verse 59-AATTTCAAGCCCTTGCTGTG-39).
KGF Quantification by ELISA
Quantification of KGF protein by ELISA of MSC supernatants,
plasma derived from peripheral blood, or lung powder from the
HSC experiment, was performed according to the manufacturer’s
instructions (R&D systems).
Statistical Analysis
Data were assessed for their suitability to be analyzed using
parametric or non-parametric statistical tests and then underwent
Student’s t-test, One-Way ANOVA, Two-Way ANOVA (with
Student-Newman-Keuls post hoc analysis) or a Two-Way Repeated
Measures ANOVA with one factor repetition (for analysis of
mouse bodyweight changes). For Ashcroft score analysis of lung
fibrosis the non-parametric Mann-Whitney test was used. P
values,0.05 were considered significant.
Results
Characterization of MSCs and Expression of KGF after
Lentiviral transduction
We first examined delivery of KGF using MSCs. Murine MSCs
were cultured as previously described [15]. After expansion by two
passages, the MSCs were transduced with KGF-eGFP (MSC-
KGF) or an eGFP control (MSC-GFP) using an inducible
lentiviral vector (to be able to compare with parallel studies in
HSCs) (Fig. 1A). In vitro experiments confirmed that the gene
expression was induced only in the presence of doxycycline as
measured by GFP expression using flow cytometry (not shown).
One week after transduction, MSCs expressing GFP were purified
by cell sorting and expanded in the presence of doxycycline. The
multipotent differentiation capacity of the transduced MSCs was
confirmed by their differentiation into adipocytes and osteoblasts
as shown by Oil Red O (adipocyte) and Alizarin Red S (osteoblast)
staining of in vitro differentiation cultures (Figure S1A).
Murine MSCs with or without KGF Decrease Collagen 1
Production but Do Not Attenuate the Histological
Damage in Bleomycin Induced Fibrosis
Previous studies have shown that early but not late delivery of
MSCs can attenuate the inflammatory response to bleomycin
induced lung damage and ameliorate the fibrotic effects. We used
MSCs to deliver KGF in an attempt to further reduce the
damaging effects of bleomycin and subsequent fibrosis. Mice were
treated with o.p. bleomycin or saline (Control) followed by the
delivery of PBS (Control) or 16106 transduced MSCs separated in
two doses: first dose by intra-venous injection of 56105 MSC-
KGF-GFP or MSC-GFP or 100 ml PBS at 8 hours after
bleomycin (day 0), and a second dose on day 3 after damage
(Fig. 1B). In order to induce the KGF expression, we added
doxycycline to the drinking water from day 0 after bleomycin
administration. Flow cytometry analysis of a portion of the MSCs
harvested for injection showed doxycyline induced GFP expression
in over 85% of both MSC-GFP and MSC-KGF-GFP (Fig. 1C).
Furthermore, we measured the KGF expression in the superna-
tants of the cultured cells by ELISA, and confirmed that injected
MSC-KGF-GFP cells but not MSC-GFP cells were secreting KGF
(Figure S1B). As bleomycin injury causes a decrease in mouse
bodyweight, we analyzed the weight of the mice over the 14 days
following damage. Although a slightly lower bodyweight loss was
observed in mice treated with MSCs, we found no significant
differences between the bleomycin treated groups (Figure S1C). In
order to localize the transduced MSCs within the lungs, anti-GFP
immunohistochemistry was performed in lung sections 14 days
after bleomycin administration. GFP staining demonstrated very
low numbers of cells expressing GFP in both saline and bleomycin
treated mice (Fig. 1D, inserts). These data were confirmed by flow
cytometry of the digested left lung lobe, revealing approximately
0.1% of total lung cells were GFP positive (Figure S1D). Consistent
with the low levels of MSC engraftment at 14 days, no significant
difference in the KGF mRNA level among the bleomycin groups
was detected (Figure S1E). Systemic KGF levels were also assessed
by measuring KGF in plasma from peripheral blood samples. No
KGF protein was detectable by ELISA in any of the samples tested
(data not shown); these data suggest that little or no KGF is
reaching the systemic circulation.
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Figure 1. In vitro characterization of MSCs expressing KGF and their therapeutic potential in bleomycin-induced lung injury. A)
Schematic representation of the lentiviral vector used in this study. B) Schematic of experimental design. C57Bl/6 mice received bleomycin (BLM) by
o.p. instillation, followed 8 h later by i.v. injection of 0.56106 MSCs-eGFP or MSCs-KGF-eGFP, repeated three days later and then sacrificed at day 14.
C) eGFP expression of transduced MSCs at the day of injection. D) Rare MSCs-eGFP and MSC-KGF-eGFP cells are detected in the lung after injury by
immunohistochemistry (brown stained cells, arrows). (Scale bar = 100 mm. Inserts, scale bar = 50 mm). E) Representative images of Martius Scarlet Blue
stained lung sections. (Scale bar = 100 mm). F) Comparison of morphometric analysis using Ashcroft Score, 14 days after bleomycin, showed no
reduction of fibrosis with transduced MSCs. Bars represent means 6 SEM. G) RT-PCR analysis for Collagen 1a1 mRNA from lung extracts showed
significant differences between bleomycin and bleomycin +MSCs-KGF-eGFP groups while H) there was no difference in lung collagen accumulation
as measured by reverse-phase HPLC quantification of lung hydroxyproline. Statistical differences were detected between saline and bleomycin
groups regardless of MSC administration (*p,0.05). Bars represent means 6 SEM. Statistically significant differences are indicated by p-values from a
One-Way ANOVA test.
doi:10.1371/journal.pone.0008013.g001
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Histological examination using H&E and Martius Scarlet Blue
Staining of lung architecture and collagen deposition revealed
typical features of bleomycin damage in all three treated groups
(Fig. 1D and E). Modified Ashcroft scores were performed, in a
blinded fashion, to quantify lung damage. This analysis revealed
no differences between the bleomycin groups demonstrating that
neither MSC-GFP nor MSC-KGF-GFP improved the lung
architecture (Fig. 1F). To determine if the MSCs were able to
reduce the characteristic collagen deposition in the lungs after
bleomycin-induced damage in mice, we performed real time PCR
for Collagen-1a1 mRNA and a biochemical quantification of the
collagen protein content by HPLC. Surprisingly, we found that
both MSC-GFP and MSC-KGF-GFP reduced collagen mRNA
levels but only MSC-KGF-GFP treated mice showed a statistically
significant decrease compare to the bleomycin only treated group
(Fig. 1G). In contrast, HPLC determination of hydroxyproline
content, as a surrogate marker for collagen protein levels,
demonstrated no significant differences between the bleomycin
groups – in agreement with the Ashcroft scores. Bleomycin
treatment per se resulted in significantly increased levels of left
lung collagen, irrespective of MSC treatment (Fig. 1H). Taken
together, in our experiments MSCs do not reduce the accumu-
lation of lung collagen or the severity of fibrosis, at least at 14 days
post bleomycin. However, given the apparent reduction in
collagen-1a1 mRNA levels at 14 days, we cannot rule out that
ongoing fibrosis may be attenuated at later time points.
Hence we have efficiently induced both in vitro and in vivo GFP
and KGF expression in transduced MSCs. However the delivery
of MSCs, injecting twice at early stages after bleomycin exposure
(days 0 and 3), did not reduce the fibrosis assessed biochemically
and histologically.
Characterization of Lentiviral Ttransduction of KGF-eGFP
into Lineage Negative Hematopoietic Stem Cells
In parallel to the experiments using MSCs, and in order to
address the therapeutic potential of other bone marrow cell
populations, we explored the possibility of using bone marrow
transduced HSCs as a cell therapy vehicle. In these experiments
we harvested and transduced lineage negative (Lin-) hematopoietic
stem cells with KGF-expressing lentivirus (HSC-KGF) or the
eGFP control (HSC-GFP; Mock) and then performed bone
marrow transplants (BMT). Seven weeks after BMT we admin-
istered doxycycline in drinking water to induce KGF and GFP
expression, followed by bleomycin damage at week 9 after BMT
(Fig. 2A). HSC-KGF transplanted mice received o.p. saline (n = 3)
or bleomycin (n = 6); a third group of mice received bleomycin
only (n = 6).
In vitro treatment of the Lin- HSCs with doxycycline revealed
GFP expression rates between 40-50% with both lentiviruses,
compared with less than 0.4% in no doxycycline controls,
demonstrating good transduction rates and an efficient and tightly
controlled gene induction by doxycycline (Fig. 2B). Importantly,
KGF expression did not affect the colony formation and
differentiation potential of HSCs compared to Mock in methyl-
cellulose assays (Fig. 2C), confirming that KGF did not alter the
potential of these cells to differentiate into the mature blood
lineages in vitro.
Eight weeks post-BMT, we analyzed blood chimerism by flow
cytometry using CD45.1 (donor cells) and CD45.2 (recipient cells)
markers. The average degree of chimerism in these mice was 53%,
and after one week of doxycycline treatment approximately 10%
of all the donor circulating cells were expressing GFP (Table 1 and
Figure S2A). Recipient mice showed donor bone marrow multi-
lineage engraftment and, in mice treated with doxycycline, an
efficient transduction in each lineage (granulocytes, macrophages
and lymphocytes). The GFP levels within these cell populations
were similar to the GFP levels from the total donor blood cells, as
measured by flow cytometry (Table 1 and Figure S2B).
Figure 2. Lineage negative HSCs KGF-eGFP transduction and
differentiation potential. A) Schematic of experimental design. 8
weeks-old C57Bl/6 mice were lethally irradiated followed by intrave-
nous injection of 0.66106 transduced lin- HSCs (BMT). 7 weeks after
BMT, mice received doxycycline in drinking water to induce gene
expression and chimerism was analysed one week later. 9 weeks after
BMT, mice received bleomycin by o.p. instillation and were sacrificed at
day 14. B) Flow cytometry analysis showed eGFP expression in vitro
after adding doxycycline to lin- HSCs transduced with LV-eGFP (MOCK)
and LV-KGF-eGFP. C) Amount and type of colonies in methylcellulose
after culture of transduced Lin- HSCs with MOCK or KGF-eGFP was
unchanged. BFU-E, erytrocyte; CFU-G, granulocyte; CFU-M, myeloid;
CFU-GM, mixed granulocyte and myeloid.
doi:10.1371/journal.pone.0008013.g002
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Transplantation of Lineage Negative Cells Expressing KGF
Protects from Bleomycin Induced Fibrosis
Nine weeks post-BMT mice were treated with o.p. bleomycin
(2 mg/kg) or saline (Control), and sacrificed 14 days later. To
localize bone marrow derived cells from the transduced HSCs, we
analysed GFP expression within the damaged lungs. Immunohis-
tochemical analysis of the lung showed BMDCs expressing GFP
only in the HSC-KGF mice treated with doxycycline at a low
percentage (Fig. 3A). This result was confirmed by flow cytometry,
where approximately 2% of cells were GFP positive (Figure S3A
and Table 2).
Bleomycin injury alone caused a significant decrease in mouse
bodyweight over time compared with saline-treated animals (effect
of treatment/time, p,0.05), with individual timepoints from day 7
onwards being highly significantly different. The change in
bodyweight for HSC-KGF transplanted bleomycin-treated ani-
mals was significantly different from both saline-treated and
bleomycin only-treated animals, suggesting a partial amelioration
in bodyweight loss with HSC-KGF transplantation (effect of
treatment/time, p,0.05), although no individual time points were
significantly different (Figure S3B).
Fourteen days after bleomycin administration, lungs were
harvested and histologically assessed with H&E and Martius
Scarlet Blue staining (Fig. 3A and B). Modified Ashcroft scoring,
determined in a blinded fashion, showed that HSC-KGF treated
mice had significantly lower Ashcroft scores than those receiving
bleomycin alone (Fig. 3C). The reduction in fibrosis was not only
demonstrated by histology, but also by significantly reduced
Collagen 1a1 mRNA levels compared to the bleomycin alone
(p,0.012; Fig. 3D). HPLC quantification of hydroxyproline
content demonstrated a significant increase in total lung collagen
in mice given bleomycin alone compared with saline-treated
animals (p = 0.0179; Fig. 3E), but there was no significant
difference between saline-treated animals and HSC-KGF trans-
planted mice given bleomycin. These data suggest that HSC-KGF
transplantation can attenuate lung collagen accumulation in this
model, and confirms the efficiency of using these bone marrow
derived stem cells expressing KGF as a system to reduce fibrosis.
Lineage Negative Cells Expressing KGF Induce Epithelial
Proliferation
KGF has been shown to induce type II pneumocyte
proliferation both in vitro and in vivo [37,47,48]. Based on this
potential, we were interested to determine whether the ameliora-
tion obtained from damage induced by bleomycin was associated
with an increase in type II cell proliferation. To address this
question, dual immunofluorescence for the proliferation marker
Ki67 and the type II cell marker pro-SPC was performed and
double positive cells counted from 6 independent areas, by
histopathologists blinded to the mouse treatments (Fig. 4A). As
lung tissue presents high levels of auto-fluorescence, tissues were
treated with Sudan Black after the immunohistochemistry (See
Materials and Methods). We detected a significant increase in
double positive cells in bleomycin treated HSC-KGF mice
compared to bleomycin controls (p = 0.0002) (Fig. 4C). Interest-
ingly, in light photomicrographs of the analyzed areas, the
proliferating epithelial cells were observed close to fibrotic lesions
or regenerating areas surrounding lesions (Fig. 4B). Moreover,
there was also a small but significant increase in double positive
cells in HSC-KGF-saline animals compared to saline controls
(p = 0.0008) suggesting some effect of KGF once activated by
doxycycline in non-damaged epithelium and hence the potential
importance of an inducible system. In order to correlate the
increase of proliferation with KGF expression, we performed real
time PCR for KGF. This analysis revealed an increase in KGF
mRNA levels between HSC-KGF bleomycin treated mice
compared to bleomycin treated controls, although this just failed
to reach significance (Fig. 4D). To further investigate the presence
and localisation of KGF in the fibrotic lung, we investigated KGF
protein levels by immunohistochemistry and ELISA. We detected
a low frequency of KGF-expressing cells in the lungs of mice from
the saline group but, as expected, a higher frequency of KGF
positive cells was detected in both bleomycin groups, particularly
in fibrotic lesions and the surrounding area (Figure S4A, positive
cells indicated with arrows). As KGF is a secreted protein,
quantification of positive cells between the bleomycin groups was
difficult to assess. However, in order to demonstrate that a sub-
population of KGF positive cells originated from the transduced
HSC-derived bone marrow cells, we performed immunohisto-
chemistry for GFP on serial sections (dual staining was not
possible, due to the incompatibility of staining protocols for KGF
and GFP). Interestingly, we detected GFP positive cells that co-
localised with KGF immunoreactivity, in both saline and
bleomycin groups that were given doxycycline (Figure S4B,
positive cells indicated with arrows).
We also measured the KGF protein levels in the lungs by
ELISA of lung homogenates. KGF protein levels were reasonably
high in the bleomycin group, and there was a trend for increased
KGF protein levels in mice transplanted with HSC-KGF cells
despite lower levels of fibrosis (Figure S4C). Interestingly KGF
levels correlated with hydroxyproline content of the lungs after
bleomycin injury in controls but not in HSC-KGF treated mice
(which we would have predicted to be lower due to the reduced
injury), suggesting that the raised levels were indeed due to the
local KGF delivery by bone marrow derived cells (Figure S4D).
These data are in agreement with the increased KGF mRNA
levels detected by real time PCR, as well as the presence of GFP
positive cells co-localising with KGF expression. Importantly,
KGF was not detectable in peripheral blood ELISA suggesting a
local rather than systemic therapeutic effect.
Lineage Negative Cells Expressing KGF Reduce Pro-
Inflammatory Cytokines, Chemokines and a-Smooth
Muscle Actin Positive Myofibroblasts
To assess effects on inflammation we examined levels of the pro-
inflammatory cytokine TNF-a and the leukocyte chemoatractants
CCL2, CCL9 by real time PCR. Bleomycin treated HSC-KGF
mice had a very clear reduction of the mRNA levels of all three
cytokines compared to bleomycin treated control mice (Fig. 5A),
suggesting that KGF expression may reduce inflammation.
It is also well established that the central effector cell in the
development of lung fibrosis is the myofibroblast. These cells are
derived from the differentiation of fibroblasts, under the influence
Table 1. Multilineage engraftment 8 weeks after bone
marrow transplantation with transduced Lineage negative
HSCs.
Chimerism
GFP
donor
cells
GFP
Granulocytes
from Donor
GFP
Macrophages
from donor
GFP
Lymphoid
from Donor
53.32610.33 9.7365.12 17.0167.79 16.9867.75 7.8264.29
Expressed in percentages and standard deviations.
*All mice were exposed to doxycycline in drinking water for a week pre analysis
(n = 15).
doi:10.1371/journal.pone.0008013.t001
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of pro-fibrotic factors such as TGF-beta. These cells are the main
cell type responsible for the synthesis and deposition of
extracellular matrix and the resultant structural remodelling that
leads to the loss of alveolar function [49]. We performed
immunohistochemical analysis to detect a –smooth muscle actin
(a –sma) in the fibrotic areas of the lungs and detected a reduction
in HSC-KGF treated mice compared with bleomycin alone
(Fig. 5B). These data not only support the reduction of fibrosis
observed and quantified by Ashcroft score (Fig. 3B and 3C), but
also provide indirect evidence for the effect of KGF expression by
HSCs on the reduction of factors, such as TGF-b1, responsible for
mediating the pro-fibrotic effect.
Discussion
The main purpose of this work was to demonstrate, as a proof of
concept, that bone marrow transplantation using an inducible
gene transfer system to deliver KGF could provide a successful
therapy for lung injury in mice. We chose to deliver KGF due to
its established role in pulmonary epithelial repair [37,47,48]. KGF
Figure 3. Therapeutic potential of KGF expressing Lin- HSCs in bleomycin-induced lung fibrosis in mice. A) GFP immuno-staining 14
days after bleomycin demonstrated brown stained cells (arrows) in mice given doxycycline in drinking water. (Scale bars = 100 mm; inserts, scale
bars = 50 mm). B) Martius Scarlet Blue stained lung sections showed a reduction of fibrosis in mice expressing KGF-eGFP. Scale bar = 100 mm. C) Semi-
quantitative representative morphometric analysis using Ashcroft Score, confirmed the reduction in lung fibrosis when KGF is expressed by bone
marrow cells. (p = 0.03; Mann-Whitney). D) RT-PCR analysis for Collagen 1a1 mRNA from lung extracts showed reduced collagen in the bleomycin +
KGF-eGFP group versus bleomycin only group (p = 0.012; One-Way ANOVA). E) KGF attenuated lung collagen accumulation after bleomycin
instillation in mice, as measured by reverse-phase HPLC quantification. A statistical significant increase was detected in saline versus bleomycin only
group, but not the HSC-KGF treated group. (p = 0.0179, One-Way ANOVA). All bars represent means 6 SEM.
doi:10.1371/journal.pone.0008013.g003
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induces type II cell proliferation in rabbits, rats and mice
[38,42,48] with an associated increase in the protective surfactant
proteins [38,50]. Furthermore, KGF improves alveolar repair by
enhancing cell spreading and motility [51].
As we believe that different bone marrow cell populations may
have different therapeutic effects in the lung, we decided to study
in parallel, MSCs and HSCs as vehicles to deliver KGF into the
lung. The successful contribution of BMDCs into normal lung
[11,13], and after induced-lung injury [29,31] encouraged us to
attempt an HSCs-based gene therapy in the bleomycin-induced
lung fibrosis model.
In order to eliminate the potential long-term side effects of KGF
on HSC development, we opted for an inducible Tet-On lentiviral
vector. We showed first that this system was working efficiently i.e.
the transduced cells can be induced in vitro to express GFP and
KGF and that the system was not leaky. The transduced cells
repopulated the bone marrow of recipient mice and could be
activated in vivo with doxycycline, as confirmed by GFP expression
using flow cytometry. GFP (hence KGF) expressing cells were
detected in approximately 10% of donor cells in the peripheral
blood of these mice.
Based on previous reports, we expected that the delivery of
KGF using MSCs in particular would be beneficial, as MSCs
themselves have been also shown to have immuno-suppressive
properties. Hence this therapy could be viewed as a combina-
tion of the MSC’s immuno-suppression of the pro-inflammatory
response and KGF mediated stimulation of epithelial prolifer-
ation and reduction of apoptosis [52]. An alternative strategy of
reducing inflammation has successfully been used in the LPS
induced acute lung injury model using MSCs to deliver
Angiopoietin 1 [53]. Here MSCs reduced the inflammatory
cell count in bronchial alveolar lavage (BAL) and also the level
of pro-inflammatory cytokines. Interestingly in this study
neither treatment with MSCs nor MSCs delivering Angiopoie-
tin 1 significantly improved the histological score of the lung
damage.
The failure of MSCs to alter the histopathological damage
scores in our experiments is intriguing. MSCs can inhibit the
activation of immune cells resulting in a reduction of inflamma-
tory response. Mei et al noted that the delivery of MSCs resulted
in near complete reduction of tissue cytokine expression in their
LPS induced acute lung injury model [53] while others have
noted reduced inflammation in the lung after MSC delivery in the
bleomycin model [8,17,18]. It has been noted that MSCs must be
delivered early in the bleomycin model to attenuate the resulting
fibrosis [8,18] correlating with the early inflammatory steps in the
pathogenesis of bleomycin-induced lesions [54]. We delivered
MSCs at the time of bleomycin injury and 3 days later. While the
end points of our experiments have not allowed an investigation
on early changes in inflammation the lack of an impact in the
development of fibrotic lesions was clear although the reduction of
Collagen 1a1 mRNA expression does suggest some sub-clinical
effect. It has been shown that increased engraftment of the
injected MSCs depend on tissue injury. The engraftment of
endogenous eGFP-labelled MSC one week after endotoxin [30]
and 3 weeks after elastase inhalation [9] was seen after the
pulmonary insult but not in controls. However in our study and in
some other recent studies very low engraftment levels in both
undamaged and damaged lung at 14 days have been observed
[18,53,55].
For the HSC-based gene therapy approach, we induced KGF/
GFP expression before bleomycin administration based on
previous studies in which they found that delivery of recombinant
KGF early in the disease pathogenesis was essential for its
amelioration [38]. In this study we show a significant reduction of
the pathological hallmarks of bleomycin-induced lung fibrosis
using HSCs-KGF, with a clear reduction in collagen 1a1 mRNA
and collagen content, as well as in lung damage using a histological
score analysis. Importantly, these results are reflected in the health
state of the mice, with doxycycline treated mice showing reduction
in weight loss. Moreover, we detected a significant increase in the
mitogenic activity of alveolar type II cells in those mice with
proliferating type II cells associated with fibrotic foci. We
demonstrated the presence of KGF and GFP double positive cells
in the lungs of mice treated with doxycycline demonstrating bone
marrow derived cells within areas of damage expressing KGF.
These data support the idea that the reduction in fibrosis observed
may be due to, at least in part, the mitogenic capacity of KGF on
type II alveolar cells. When we measured the KGF protein from
the lungs extracts by ELISA, we detected an increase of KGF in
the mice treated with HSC-KGF. However no protein was
detected in the peripheral blood in any of the mice (data not
shown), supporting the idea that the protective effect of KGF in
the lungs is local rather than systemic. We also show a reduction in
the expression of the pro-inflammatory cytokine TNF-a, and
leukocyte chemoattractants CCL-2 and CCL-9 and finally, a
reduction of a-sma in the fibrotic foci of the lungs from the mice
treated with HSC-KGF, indicating a possible reduction of the pro-
fibrotic effects of TGF-b1, a key factor in lung fibrosis.
Although several groups have used constitutive lentiviruses to
tranduce HSCs for the treatment of inherited and acquired severe
hematological or immunological disorders [56], very few groups
have used this strategy for the treatment of lung diseases. Recently
Zhang et al, have been able to treat pulmonary metastatic tumors
in mice using lentiviral-vector transduced HSCs [57]. However,
there are no reports in primary lung disease models of using bone
marrow transplantation of lentivirus-transduced HSCs.
Of course, bone marrow transplantation is a rather drastic step
for the treatment of pulmonary fibrosis in humans, and may not be
the most practical strategy to be used clinically. However, we
strongly believe that our results in this mouse model show that
gene therapy for diffuse lung diseases is possible with hematopoi-
etic stem cells, and that experiments are warranted to try and
determine if a single group of differentiated cells is capable of
similar results.
Table 2. Donor blood cells and donor GFP positive blood cells from single cell lung suspensions.
Group Donor Blood Cells GFP donor Blood cells GFP non Blood cells Recipient Blood cells Total blood Cells/lung
BLM 13.0564.47 0.1860.10 0.0860.007 12.1465.15 25.1962.16
BLM + KGF-eGFP 17.163.56 1.6860.73 1.0861.09 10.0262.41 27.1365.14
Numbers expressed in percentages and standard deviations. Freshly isolated lung cells were used for flow cytometry analysis. Similar percentage of total and donor
blood cells was detected in the bleomycin groups.
doi:10.1371/journal.pone.0008013.t002
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Supporting Information
Figure S1 Characterization of MSCs and transduction analysis
with eGFP and KGF-eGFP. A) Adipocyte (Oil red-O staining) and
Osteogenic (Alizarin red staining) differentiation of transduced
MSCs. (10x objective using inverted microscope). B) KGF protein
levels were detected by ELISA from the supernatant of MSCs-
KGF-eGFP but not from MSCs-eGFP on the day of injection into
C57B/6 mice. C) Body weights post bleomycin treatment showed
no significant differences in the weight loss induced by bleomycin.
D) Flow cytometry to detect eGFP expressing MSCs from freshly
isolated lung cells 14 days after bleomycin showed almost no eGFP
cells in any group. E) qRT-PCR analysis for KGF mRNA from
lung extracts shows a modest increase in KGF expression in
Figure 4. Bone marrow derived cells expressing KGF induced alveolar epithelial cell proliferation within the injured lung. A) Double
immunofluorescence with lung epithelial type II marker Surfactant Protein C (SP-C) (green) and proliferation marker Ki-67 (red) on paraffin lung
sections, 14 days after bleomycin administration. Bone marrow cells expressing KGF increased proliferation of alveolar type II cells in both saline and
BLM groups. Arrows indicate proliferating lung epithelial cells. (Scale bars = 100 mm; inserts, scale bars = 50 mm). B) Contiguous light microscopy
photomicrographs corresponding to A. C) Quantification of double positive SP-C and Ki-67 stained cells showed an increase in proliferating epithelial
cells when KGF is expressed. Bars represent mean from 6-areas/lung sections counted 6 SEM. (P-values from Two-Way ANOVA). D) qRT-PCR analysis
for KGF mRNA from lung extracts showing increased levels of KGF in doxycycline treated mice. Bars represent means6 SEM. (P-values from Student’s
T-test).
doi:10.1371/journal.pone.0008013.g004
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MSCs-KGF-eGFP mice compared to control groups. Bars
represent means +/2 SEM.
Found at: doi:10.1371/journal.pone.0008013.s001 (1.56 MB TIF)
Figure S2 Chimerism, transduction and multilineage in vivo
engraftment analysis of HSCs. A) Flow cytometry of peripheral
blood from recipient mice 7 weeks after BMT plus one week with
doxycycline treatment. Donor KGF-eGFP expressing blood cells
were detected within the donor bone marrow population labelled
with CD45.1 in the presence of doxycycline. B) Multilineage
engraftment analysis by flow cytometry. Blood markers for
macrophages (Mac-1), granulocytes (Gr-1) and lymphocytes
(CD-3) were used together with the donor marker (CD45.1). In
each differentiated subpopulation, KGF-eGFP expressing cells
were detected, demonstrating an efficient bone marrow repopu-
lation and in vivo induction.
Found at: doi:10.1371/journal.pone.0008013.s002 (7.89 MB TIF)
Figure S3 Expression of KGF-GFP in the lungs reduces body
weight loss in mice after bleomycin administration. A) Flow
cytometry of left lung digests detecting KGF-eGFP expressing cells
14 days after bleomycin administration. B) Body weights post
bleomycin treatment showed doxycycline-induced expression of
KGF from BMDC (BLM+KGF) reduces the weight loss induced
by bleomycin.
Found at: doi:10.1371/journal.pone.0008013.s003 (4.63 MB TIF)
Figure S4 Increased detection of KGF positive cells in mice
expressing HSC-KGF correlates with GFP positive cells. A)
KGF immuno-staining 14 days after bleomycin demonstrated
frequent brown stained cells (arrows) in mice treated with
doxycyline. (Scale bars = 50 um; inserts, scale bars = 25 um). B)
GFP staining in serial lung sections showed a correlation of
KGF and GFP expression in mice treated with doxycyline only.
(Scale bar = 50 um, inserts, scale bars = 25 um). C) KGF ELISA
from lung powder showed higher levels of KGF in mice treated
with doxycyline. D) Correlation of KGF protein levels,
measured by ELISA, with the collagen content of the lungs
after bleomycin injury. Linear correlation values are indicated
for each group.
Found at: doi:10.1371/journal.pone.0008013.s004 (6.03 MB TIF)
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Figure 5. Bone marrow derived cells expressing KGF reduce inflammatory cytokines, macrophage chemo-attractants and a-
sma. A) qRT-PCR analysis for inflammatory cytokines revealed significant reductions of TNF-a and CCL-2 and CCL-9 chemokine mRNA in lung
extracts from doxycycline treated BLM-KGF mice compared with BLM treatment alone. Bars represent means 6 SEM. (P-values from One-Way
ANOVA). B) a-sma stained lung sections showed a reduction of myofibroblast-type cells in the lungs of mice treated with KGF-eGFP. Scale
bar = 50 mm.
doi:10.1371/journal.pone.0008013.g005
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